Title: Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Journal: Expert opinion on drug metabolism & toxicology 20121101
Title: Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).
Journal: The Analyst 20120807
Title: Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.
Journal: Annals of internal medicine 20120619
Title: Role of M2 and M3 muscarinic acetylcholine receptor subtypes in activation of bladder afferent pathways in spinal cord injured rats.
Journal: Urology 20120501
Title: Contractions of the mouse prostate elicited by acetylcholine are mediated by M(3) muscarinic receptors.
Journal: The Journal of pharmacology and experimental therapeutics 20111201
Title: Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol.
Journal: Urology 20111201
Title: Time-to-effect with darifenacin in overactive bladder: a pooled analysis.
Journal: International urogynecology journal 20111201
Title: Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Journal: Neurourology and urodynamics 20111101
Title: A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Journal: British journal of clinical pharmacology 20110801
Title: Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay.
Journal: Journal of the American Geriatrics Society 20110301
Title: Patient experience with darifenacin - results of a short-term community-based survey in managing overactive bladder.
Journal: Current medical research and opinion 20110201
Title: Activation state of the M3 muscarinic acetylcholine receptor modulates mammalian odorant receptor signaling.
Journal: Science signaling 20110111
Title: Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.
Journal: Digestive diseases and sciences 20110101
Title: Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.
Journal: Neurourology and urodynamics 20110101
Title: Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
Journal: Urology 20101001
Title: Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Journal: Life sciences 20100731
Title: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans.
Journal: American journal of physiology. Gastrointestinal and liver physiology 20100701
Title: Comparison of human and porcine gastric clasp and sling fiber contraction by M2 and M3 muscarinic receptors.
Journal: American journal of physiology. Gastrointestinal and liver physiology 20100401
Title: Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.
Journal: American journal of physiology. Gastrointestinal and liver physiology 20091201
Title: Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study.
Journal: International urogynecology journal and pelvic floor dysfunction 20091101
Title: Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
Journal: BJU international 20091001
Title: Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice.
Journal: British journal of pharmacology 20090401
Title: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.
Journal: The Journal of pharmacology and experimental therapeutics 20090301
Title: In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.
Journal: British journal of pharmacology 20090301
Title: Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Journal: Neurourology and urodynamics 20090101
Title: Use of antimuscarinics in the elderly.
Journal: TheScientificWorldJournal 20090101
Title: Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
Journal: Journal of cardiovascular pharmacology and therapeutics 20081201
Title: Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
Journal: International journal of clinical practice 20081101
Title: Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
Journal: International journal of clinical practice 20081101
Title: Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity.
Journal: International urogynecology journal and pelvic floor dysfunction 20081001
Title: Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin.
Journal: Clinical interventions in aging 20080901
Title: Interstitial granulomatous dermatitis associated with darifenacin.
Journal: Journal of drugs in dermatology : JDD 20080901
Title: Clinical relevance of health-related quality of life outcomes with darifenacin.
Journal: BJU international 20080701
Title: Activated cholinergic signaling provides a target in squamous cell lung carcinoma.
Journal: Cancer research 20080615
Title: A journey to continence: a case study of overactive bladder syndrome.
Journal: Urologic nursing 20080601
Title: A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.
Journal: International journal of clinical practice 20080401
Title: The effect of darifenacin on overactive bladders in female and male rabbits.
Journal: International urology and nephrology 20080101
Title: Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
Journal: Neurourology and urodynamics 20080101
Title: Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
Journal: Current medical research and opinion 20071101
Title: Comparative in vivo uroselectivity profiles of anticholinergics, tested in a novel anesthetized rabbit model.
Journal: European journal of pharmacology 20071031
Title: Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
Journal: Current medical research and opinion 20071001
Title: [The recommendations of the Polish Gynecologic Society regarding the use of darifenacin, selective muscarinic antagonists in the treatment of overactive bladder].
Journal: Ginekologia polska 20071001
Title: Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
Journal: European urology 20070901
Title: Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
Journal: European urology 20070901
Title: Editorial comment on: effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
Journal: European urology 20070901
Title: Cholinergic activation of phasic activity in the isolated bladder: possible evidence for M3- and M2-dependent components of a motor/sensory system.
Journal: BJU international 20070901
Title: Pharmacologic management of overactive bladder.
Journal: Clinical interventions in aging 20070901
Title: Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction.
Journal: European urology 20070801
Title: Update on drugs for overactive bladder syndrome.
Journal: Drug and therapeutics bulletin 20070601
Title: M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion.
Journal: Cancer research 20070415
Title: [Treatment of overactive bladder in elderly and old people].
Journal: Der Urologe. Ausg. A 20070401
Title: Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.
Journal: Expert opinion on pharmacotherapy 20070301
Title: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Journal: The Journal of urology 20070201
Title: M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors.
Journal: Neurourology and urodynamics 20070101
Title: Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Journal: Biological & pharmaceutical bulletin 20070101
Title: [Darifenacine--Emselex].
Journal: Journal de pharmacie de Belgique 20070101
Title: In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice.
Journal: Life sciences 20061214
Title: New developments in the treatment of urinary incontinence.
Journal: Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20061201
Title: Treatment of overactive bladder in the aging population: focus on darifenacin.
Journal: Clinical interventions in aging 20061201
Title: Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
Journal: BJU international 20061101
Title: Darifenacin: Pharmacology and clinical usage.
Journal: The Urologic clinics of North America 20061101
Title: Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Journal: Naunyn-Schmiedeberg's archives of pharmacology 20061101
Title: Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
Journal: European urology 20060801
Title: [Anticholinergics for overactive bladder: does subtype selectivity play a role?].
Journal: Der Urologe. Ausg. A 20060701
Title: Regulation of bladder muscarinic receptor subtypes by experimental pathologies.
Journal: Autonomic & autacoid pharmacology 20060701
Title: Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
Journal: International urogynecology journal and pelvic floor dysfunction 20060501
Title: Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
Journal: The American journal of medicine 20060301
Title: M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder.
Journal: The Journal of pharmacology and experimental therapeutics 20060201
Title: M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder.
Journal: The Journal of pharmacology and experimental therapeutics 20060201
Title: New drugs 06, part I.
Journal: Nursing 20060201
Title: Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
Journal: International journal of clinical practice 20060101
Title: The clinical pharmacokinetics of darifenacin.
Journal: Clinical pharmacokinetics 20060101
Title: Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
Journal: BJU international 20051101
Title: Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Journal: European urology 20050901
Title: Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
Journal: World journal of urology 20050901
Title: QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.
Journal: Journal of clinical pharmacology 20050901
Title: Solifenacin and darifenacin for overactive bladder.
Journal: Obstetrics and gynecology 20050801
Title: Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.
Journal: European urology 20050701
Title: Darifenacin in the treatment of overactive bladder.
Journal: International journal of clinical practice 20050701
Title: Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder.
Journal: Naunyn-Schmiedeberg's archives of pharmacology 20050701
Title: Darifenacin in the treatment of overactive bladder.
Journal: Drugs of today (Barcelona, Spain : 1998) 20050701
Title: New treatment options for overactive bladder.
Journal: South Dakota journal of medicine 20050601
Title: A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Journal: BJU international 20050501
Title: Increased warning time with darifenacin: a new concept in the management of urinary urgency.
Journal: The Journal of urology 20050401
Title: Solifenacin and darifenacin for overactive bladder.
Journal: The Medical letter on drugs and therapeutics 20050314
Title: An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
Journal: BJU international 20050301
Title: Assessment of cognitive function of the elderly population: effects of darifenacin.
Journal: The Journal of urology 20050201
Title: New drugs: palifermin, eszopiclone, and darifenacin hydrobromide.
Journal: Journal of the American Pharmacists Association : JAPhA 20050101
Title: [Overactive bladder].
Journal: Krankenpflege Journal 20050101
Title: Mechanisms mediating cholinergic antral circular smooth muscle contraction in rats.
Journal: World journal of gastroenterology 20041115
Title: Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder.
Journal: Expert opinion on investigational drugs 20041101
Title: Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.
Journal: Current urology reports 20041001
Title: Elevating our therapeutic expectations in overactive bladder.
Journal: Journal of the American Academy of Nurse Practitioners 20041001
Title: In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Journal: European journal of pharmacology 20040525
Title: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Journal: European urology 20040401
Title: Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.
Journal: British journal of clinical pharmacology 20040201
Title: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Journal: Life sciences 20040102
Title: Darifenacin: in the treatment of overactive bladder.
Journal: Drugs & aging 20040101
Title: Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability.
Journal: British journal of clinical pharmacology 20031201
Title: Pharmacological effects of darifenacin on human isolated urinary bladder.
Journal: Pharmacology 20031201
Title: Update on overactive bladder: pharmacologic approaches on the horizon.
Journal: Current urology reports 20031001
Title: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Journal: Naunyn-Schmiedeberg's archives of pharmacology 20020801
Title: Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
Journal: European journal of pharmacology 19980522
Title: Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors.
Journal: Journal of receptor and signal transduction research 19970101
Title: Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418.
Title: Miller DW, et al. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. Neurourol Urodyn, 2011, 30(8), 1633-1638.
Title: Iijima K, et al. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol, 2007, 52(3), 842-847.
